Format

Send to

Choose Destination
Alzheimers Res Ther. 2013 Aug 14;5(4):36. doi: 10.1186/alzrt195. eCollection 2013.

Amyloid imaging in clinical trials.

Author information

1
Department of Radiology & Nuclear Medicine, VU University Medical Center Amsterdam, PO Box 7057, 1007 MB, Amsterdam, the Netherlands ; Alzheimer Center & Department of Neurology, VU University Medical Center, Amsterdam, PO Box 7057, 1007 MB, Amsterdam, the Netherlands.
2
Alzheimer Center & Department of Neurology, VU University Medical Center, Amsterdam, PO Box 7057, 1007 MB, Amsterdam, the Netherlands.
3
Department of Radiology & Nuclear Medicine, VU University Medical Center Amsterdam, PO Box 7057, 1007 MB, Amsterdam, the Netherlands.

Abstract

The possibility to map amyloid-beta, the Alzheimer's disease hallmark protein, in vivo opens the application for amyloid imaging in clinical trials with disease-modifying agents. Monitoring change in amyloid burden, particularly when potential amyloid-lowering drugs are at play, requires accurate analytical methods. Studies to date have used suboptimal methods that do not account for heterogeneous changes in flow associated with disease progression and potentially with anti-amyloid drugs. In this commentary, we discuss practical and methodological issues regarding longitudinal amyloid imaging and propose several quantitative, yet feasible, alternatives for reliable assessment of changes over time in amyloid burden.

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center